Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

96.81 -0.78 (-0.80%)
Official Closing Price Updated: 7:00 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,424,839
Open 97.28
Bid (Size) 95.76 (4)
Ask (Size) 98.00 (1)
Prev. Close 97.59
Today's Range 95.74 - 97.30
52wk Range 62.41 - 105.69
Shares Outstanding N/A
Dividend Yield 1.83%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Zoetis Stock A Good Companion For Your Portfolio? Shares Rising
Reflecting strong fundamentals, Zoetis stock boasts a best-possible A SMR Rating (sales+profit margins+return on equity) on an A-to-E scale. 
Via Investor's Business Daily
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities
Johnson & Johnson (NYSE: JNJ) has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chief Executive Officer  
Via Benzinga

Performance

YTD
+41.37%
+41.37%
1 Month
-4.80%
-4.80%
3 Month
-0.90%
-0.90%
6 Month
+21.43%
+21.43%
1 Year
+54.60%
+54.60%

More News

Read More
Obesity Drugs: Greater Weight Loss Linked to Prolonged Use of Novo Nordisk's Wegovy
Via Benzinga
Simply Good Foods: Winner in the Ozempic Weight-Loss Trend
Via MarketBeat
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative
Via Benzinga
Everyone Is Talking About This Stock. Is It a Good Long-Term Option?
Via The Motley Fool
Will NOVO-NORDISK A/S-SPONS ADR breakout?
Via Chartmill
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Via Benzinga
Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker
Via Investor's Business Daily
Ozempic vs. Mounjaro:: Battle of the bulge
Via MarketBeat
Exposures Product Safety
Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs
Via Benzinga
1 Stock-Split Stock to Buy Hand Over Fist in December, and 1 to Avoid Like the Plague
Via The Motley Fool
3 No-Brainer Growth Stocks to Buy in December
Via The Motley Fool
Pfizer Tumbles After Abandoning Weight-Loss Pill
Via Talk Markets
An Important History Lesson for Gene-Editing Investors
Via The Motley Fool
Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?
Via The Motley Fool
Advocacy for Wegovy: Denmark Signals Cost-Sharing Talks While Novo Spent Millions On Medical Community For Drug Promotion
Via Benzinga
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
Via Benzinga
Weight Loss Drugs - Novo Nordisk A Primary Beneficiary In Obesity Space Currently Controlled By Two Players, Says Analyst
Via Benzinga
Pfizer Halts Development Of Twice-Daily Weight-Loss Drug; PFE Stock Slides
Via Investor's Business Daily
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Pfizer’s Stock Is Down 44% YTD As Woes Continue
Via Talk Markets
Will Novo Nordisk Be a Trillion-Dollar Stock by 2030?
Via The Motley Fool
Novo Nordisk Sues Florida Compounding Pharmacies Over Impurities In Products Claiming To Contain Wegovy Ingredient
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.